Continuous infusion of ceftazidime with an elastomeric infusion device

American Journal of Health-System Pharmacy

Volumn 55, Issue 2, 1998, Pages 145-149

  Couldry, Rick ^a   Sanborn, Mike ^b   Klutman, Neil E ^c   Strayer, Andy H ^a,c,d  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Naples Community Hospital Healthcare System   (United States)

^c UKMC

^d Pharmaceutical Product Development   (United States)

Author keywords

Blood levels; Ceftazidime; Cephalosporins; Devices; Drug administration rate; Incompatibilities; Injections; Minimum inhibitory concentration; Pseudomonas aeruginosa; Spectrum, microbial; Stability

Indexed keywords

CEFTAZIDIME;

ADULT; CONTINUOUS INFUSION; DRUG DELIVERY SYSTEM; DRUG INFUSION; DRUG STABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SERUM BACTERICIDAL ACTIVITY;

EID: 0031889491     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.2.145     Document Type: Review

References (18)

1. Craig WA. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA. Eur J Clin Microbiol Infect Dis. 1995; 14:636-42.
2. Craig WA, Ebert SC. Minireview: continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother. 1992; 36:2577-03.
3. Craig WA, Selecting the antibiotic. Hosp Pract (Off Ed). 1993; 28(suppl 1): 16-20.
4. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol. 1990; 11:319-26.
5. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis. 1991; 74:63-70.
6. LeBel M, Spino M. Pulse dosing versus continuous infusion of antibiotics. Clin Pharmacokinet. 1988; 14:71-95.
7. Nicolau DP, Nightingale CH, Banevicius MA et al. Ceftazidime serum bactericidal activity: continuous infusion versus intermittent injections. Antimicrob Agents Chemother. 1996; 40:61-4.
8. Benko AS, Cappelletty DM, Kruse JA et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother. 1996; 40:691-5.
9. Vinks AA, Touw DJ, Heijerman HG et al. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Ther Drug Monit. 1994; 16:341-8.
10. Ceptaz package insert. Research Triangle Park, NC: Glaxo Inc.; 1993 Aug.
11. Winters ME. Clinical pharmacokinetics. Vancouver, WA: Applied Therapeutics; 1995.
12. Wade KS, Lampasona V, Mullins RE et al. Stability of ceftazidime and amino acids in parenteral nutrient solutions. Am J Hosp Pharm. 1991; 48:1515-9.
13. Myers CM, Blumer JL. Determination of ceftazidime in biological fluids by using high pressure liquid chromatography. Antimicrob Agents Chemother. 1983; 24:343-6.
14. Methods for dilution and antimicrobial susceptibility tests for bacteria that grow aerobically. Villanova, PA: National Committee for Clinical Laboratory Standards; 1990.
15. Methodology for the serum bactericidal test; tentative guidelines. Villanova, PA: National Committee for Clinical Laboratory Standards; 1992.
16. Stiles ML, Allen LV Jr, Prince SJ. Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. AM J Hosp Pharm. 1992; 49:2761-4.
17. Bednar DA, Klutman NE, Henry DW et al. Stability of ceftazidime (with arginine) in an elastomeric infusion device. Am J Health-Syst Pharm. 1995; 52:1912-4.
18. Doorne HV, Bernaards J, De Jonge P. Ceftazidime degradation rates for predicting stability in a portable infusion-pump reservoir. Am J Health-Syst Pharm. 1996; 53:1302-5.